Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …

Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …

PANTHER is a global, randomized phase 3 trial of pevonedistat+ azacitidine (n= 227) vs
azacitidine monotherapy (n= 227) in patients with newly diagnosed higher-risk …

The frequency of pathogenic/likely pathogenic (P/LP) germ line variants in patients with
myelodysplastic syndrome (MDS) diagnosed at age 40 years or less is 15% to 20 …

This phase 2 study was designed to compare systemic decitabine exposure, demethylation
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …

Next-generation sequencing (NGS) is a new technology used for DNA and RNA sequencing
and variant/mutation detection. NGS can sequence hundreds and thousands of genes or …

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms
characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of …

Myelodysplastic syndromes (MDS) include a group of clonal myeloid neoplasms
characterized by cytopenias due to ineffective hematopoiesis, abnormal blood and marrow …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation, and survival. Overexpression and overactivation of …